SCYNEXIS, Inc. Gain (Loss) on Derivative Instruments, Net, Pretax
SCYNEXIS, Inc. (SCYX) reported Gain (Loss) on Derivative Instruments, Net, Pretax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2026-03-04
- SCYNEXIS, Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-12-31 was $0.00.
- SCYNEXIS, Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-09-30 was $0.00.
- SCYNEXIS, Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- SCYNEXIS, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2024 was $196.00K.
- SCYNEXIS, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2023 was -$154.00K, a 111.70% decline from fiscal 2022.
- SCYNEXIS, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2022 was $1.32M, a 12.48% increase from fiscal 2021.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month | Gain (Loss) on Derivative Instruments, Net, Pretax 6 month | Gain (Loss) on Derivative Instruments, Net, Pretax 9 month | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $0.00 derived: sum of 2 quarters · filed 2026-03-04 | $0.00 derived: sum of 3 quarters · filed 2026-03-04 | $0.00 10-K · filed 2026-03-04 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-04 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-03-04 | $0.00 derived: sum of 4 quarters · filed 2026-03-04 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-04 | $0.00 derived: sum of 3 quarters · filed 2026-03-04 | $28.00K derived: sum of 4 quarters · filed 2026-03-04 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $0.00 derived: sum of 2 quarters · filed 2026-03-04 | $28.00K derived: sum of 3 quarters · filed 2026-03-04 | $196.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $28.00K derived: sum of 2 quarters · filed 2025-11-05 | $196.00K 10-Q · filed 2025-11-05 | $224.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $28.00K 10-Q · filed 2025-08-13 | $196.00K 10-Q · filed 2025-08-13 | $224.00K derived: sum of 3 quarters · filed 2025-08-13 | $406.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $168.00K 10-Q · filed 2025-05-15 | $196.00K derived: sum of 2 quarters · filed 2025-05-15 | $378.00K derived: sum of 3 quarters · filed 2025-05-15 | $420.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $210.00K derived: sum of 2 quarters · filed 2025-03-12 | $252.00K derived: sum of 3 quarters · filed 2025-03-12 | -$154.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $182.00K 10-Q · filed 2024-11-06 | $224.00K derived: sum of 2 quarters · filed 2024-11-06 | -$182.00K 10-Q · filed 2024-11-06 | $14.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $42.00K 10-Q · filed 2024-08-08 | -$364.00K 10-Q · filed 2024-08-08 | -$168.00K derived: sum of 3 quarters · filed 2024-08-08 | -$210.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$406.00K 10-Q · filed 2024-05-08 | -$210.00K derived: sum of 2 quarters · filed 2024-05-08 | -$252.00K derived: sum of 3 quarters · filed 2024-05-08 | -$70.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $154.00K derived: sum of 2 quarters · filed 2024-03-28 | $336.00K derived: sum of 3 quarters · filed 2024-03-28 | $1.32M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$42.00K 10-Q · filed 2023-11-13 | $140.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.12M 10-Q · filed 2023-11-13 | $518.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $182.00K 10-Q · filed 2023-08-14 | $1.16M 10-Q · filed 2023-08-14 | $560.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.96M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $980.00K 10-Q · filed 2023-05-10 | $378.00K derived: sum of 2 quarters · filed 2023-05-10 | $1.78M derived: sum of 3 quarters · filed 2023-05-10 | $2.24M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$602.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $798.00K derived: sum of 2 quarters · filed 2023-03-31 | $1.26M derived: sum of 3 quarters · filed 2023-03-31 | $1.17M 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.40M 10-Q · filed 2022-11-09 | $1.86M derived: sum of 2 quarters · filed 2022-11-09 | $1.77M 10-Q · filed 2022-11-09 | -$2.65M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $462.00K 10-Q · filed 2022-08-15 | $372.00K 10-Q · filed 2022-08-15 | -$4.05M derived: sum of 3 quarters · filed 2022-08-15 | $1.24M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$90.00K 10-Q · filed 2022-05-12 | -$4.52M derived: sum of 2 quarters · filed 2022-05-12 | $774.00K derived: sum of 3 quarters · filed 2022-05-12 | $1.47M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $864.00K derived: sum of 2 quarters · filed 2022-03-29 | $1.56M derived: sum of 3 quarters · filed 2022-03-29 | $2.26M 10-K · filed 2022-03-29 |
| 2020-09-30 | $5.29M 10-Q · filed 2021-11-10 | $5.98M derived: sum of 2 quarters · filed 2021-11-10 | $6.68M 10-Q · filed 2021-11-10 | $8.03M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $693.00K 10-Q · filed 2021-08-16 | $1.39M 10-Q · filed 2021-08-16 | $2.74M derived: sum of 3 quarters · filed 2021-08-16 | $5.06M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $700.00K 10-Q · filed 2021-05-17 | $2.04M derived: sum of 2 quarters · filed 2021-05-17 | $4.37M derived: sum of 3 quarters · filed 2021-05-17 | $5.69M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $3.67M derived: sum of 2 quarters · filed 2021-03-29 | $4.99M derived: sum of 3 quarters · filed 2021-03-29 | $1.57M 10-K · filed 2021-03-29 |
| 2019-09-30 | $2.32M 10-Q · filed 2020-11-06 | $3.65M derived: sum of 2 quarters · filed 2020-11-06 | $223.00K 10-Q · filed 2020-11-06 | $223.00K derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | $1.32M 10-Q · filed 2020-08-10 | -$2.10M 10-Q · filed 2020-08-10 | -$2.10M derived: sum of 3 quarters · filed 2020-08-10 | -$2.10M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$3.42M 10-Q · filed 2020-05-11 | -$3.42M derived: sum of 2 quarters · filed 2020-05-11 | -$3.42M derived: sum of 3 quarters · filed 2020-05-11 | -$3.42M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $0.00 derived: sum of 2 quarters · filed 2020-03-11 | $0.00 derived: sum of 3 quarters · filed 2020-03-11 | $0.00 10-K · filed 2020-03-11 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |